Side-by-side financials for ESPR and LLY. Every figure below comes from audited SEC filings and refreshed market data.
| Metric | ESPR | LLY |
|---|---|---|
| Market cap | - | $1.067 T |
| US-listed rank | - | #11 |
| Revenue (latest FY) | $403.13M | $65.18B |
| Net income (latest FY) | -$22.68M | $20.64B |
| Net margin | -5.6% | 31.7% |
| P/E (trailing FY) | - | 51.7 |
| SEC filings | 885 | 989 |
In their latest fiscal years, Esperion Therapeutics, Inc. reported $403.13M in revenue while ELI LILLY & Co reported $65.18B.
Full pages: Esperion Therapeutics, Inc. and ELI LILLY & Co, or browse the full rankings.